| Immune-related adverse events with immune checkpoint blockade: a comprehensive review JM Michot, C Bigenwald, S Champiat, M Collins, F Carbonnel, ... European journal of cancer 54, 139-148, 2016 | 2235 | 2016 |
| Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1 S Champiat, L Dercle, S Ammari, C Massard, A Hollebecque, ... Clinical Cancer Research 23 (8), 1920-1928, 2017 | 1281 | 2017 |
| Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination C Boutros, A Tarhini, E Routier, O Lambotte, FL Ladurie, F Carbonnel, ... Nature reviews Clinical oncology 13 (8), 473-486, 2016 | 1126 | 2016 |
| Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper S Champiat, O Lambotte, E Barreau, R Belkhir, A Berdelou, F Carbonnel, ... Annals of Oncology 27 (4), 559-574, 2016 | 1071 | 2016 |
| A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study R Sun, EJ Limkin, M Vakalopoulou, L Dercle, S Champiat, SR Han, ... The Lancet Oncology 19 (9), 1180-1191, 2018 | 1064 | 2018 |
| Hyperprogressive disease in patients with advanced non–small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy R Ferrara, L Mezquita, M Texier, J Lahmar, C Audigier-Valette, ... JAMA oncology 4 (11), 1543-1552, 2018 | 736 | 2018 |
| Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab C Hua, L Boussemart, C Mateus, E Routier, C Boutros, H Cazenave, ... JAMA dermatology 152 (1), 45-51, 2016 | 697 | 2016 |
| Novel patterns of response under immunotherapy E Borcoman, Y Kanjanapan, S Champiat, S Kato, V Servois, R Kurzrock, ... Annals of Oncology 30 (3), 385-396, 2019 | 489 | 2019 |
| Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors E De Martin, JM Michot, B Papouin, S Champiat, C Mateus, O Lambotte, ... Journal of hepatology 68 (6), 1181-1190, 2018 | 480 | 2018 |
| Hyperprogressive disease: recognizing a novel pattern to improve patient management S Champiat, R Ferrara, C Massard, B Besse, A Marabelle, JC Soria, ... Nature reviews Clinical oncology 15 (12), 748-762, 2018 | 395 | 2018 |
| Intratumoural administration and tumour tissue targeting of cancer immunotherapies I Melero, E Castanon, M Alvarez, S Champiat, A Marabelle Nature Reviews Clinical Oncology 18 (9), 558-576, 2021 | 365 | 2021 |
| Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer A Simonaggio, JM Michot, AL Voisin, J Le Pavec, M Collins, A Lallart, ... JAMA oncology 5 (9), 1310-1317, 2019 | 346 | 2019 |
| Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease FX Danlos, AL Voisin, V Dyevre, JM Michot, E Routier, L Taillade, ... European Journal of Cancer 91, 21-29, 2018 | 293 | 2018 |
| Cardiovascular toxicity related to cancer treatment: a pragmatic approach to the American and European cardio‐oncology guidelines J Alexandre, J Cautela, S Ederhy, GL Damaj, JE Salem, F Barlesi, ... Journal of the American Heart Association 9 (18), e018403, 2020 | 260 | 2020 |
| Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study N Delanoy, JM Michot, T Comont, N Kramkimel, J Lazarovici, R Dupont, ... The Lancet Haematology 6 (1), e48-e57, 2019 | 251 | 2019 |
| Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy S Champiat, C Ferté, S Lebel-Binay, A Eggermont, JC Soria Oncoimmunology 3 (1), e27817, 2014 | 230 | 2014 |
| Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre … S Le Burel, S Champiat, C Mateus, A Marabelle, JM Michot, C Robert, ... European Journal of Cancer 82, 34-44, 2017 | 197 | 2017 |
| Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: an open-label, phase I study L Paz-Ares, S Champiat, WV Lai, H Izumi, R Govindan, M Boyer, ... Journal of Clinical Oncology 41 (16), 2893-2903, 2023 | 165 | 2023 |
| Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies M Collins, JM Michot, FX Danlos, C Mussini, E Soularue, C Mateus, ... Annals of Oncology 28 (11), 2860-2865, 2017 | 163 | 2017 |
| Long-term survival in patients responding to anti–PD-1/PD-L1 therapy and disease outcome upon treatment discontinuation ML Gauci, E Lanoy, S Champiat, C Caramella, S Ammari, S Aspeslagh, ... Clinical Cancer Research 25 (3), 946-956, 2019 | 147 | 2019 |
